北美急性冠状动脉综合征市场,按类型(非 St 段抬高型心肌梗死、St 段抬高型心肌梗死和不稳定性心绞痛)、诊断(压力测试、血液测试、影像和其他)、治疗(药物和手术)、最终用户(医院和诊所、诊断中心、学术机构和其他)划分 - 行业趋势和预测到 2029 年。
北美急性冠状动脉综合征市场分析与洞察
北美急性冠状动脉综合征市场预计将在 2022 年至 2029 年的预测期内实现显着增长。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,该市场的复合年增长率为 5.4%,预计到 2029 年将达到 59.1097 亿美元。推动急性冠状动脉综合征市场增长的主要因素是冠状动脉疾病、缺血性心脏病和血管疾病等慢性疾病患病率的上升、老年人口的增长、市场参与者提供的广泛产品,引领急性冠状动脉综合征市场在未来增长。
急性冠状动脉综合征是指心脏血流量减少的一组疾病。与 ACS 相关的疾病包括 ST 段抬高型心肌梗死 (STEMI)、非 ST 段抬高型心肌梗死 (NSTEMI) 和不稳定型心绞痛。它是一种冠心病 (CHD),占 35 岁以上人群死亡总数的三分之一。某些形式的 CHD 可能没有症状,但 ACS 始终有症状。
急性冠状动脉综合征(ACS)是冠心病(CHD)的一种表现,通常是由于冠状动脉中的斑块破裂(动脉粥样硬化)所致。该病的常见危险因素包括吸烟、高血压、糖尿病、高脂血症、缺乏运动、家庭肥胖和营养不良。可卡因滥用也会导致血管痉挛。早期心肌梗塞家族史(55 岁)也是高风险因素。
北美急性冠状动脉综合征市场报告提供了市场份额、新发展、国内和本地市场参与者的影响的详细信息,分析了新兴收入来源、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预期目标。
报告指标 |
细节 |
预测期 |
2022 至 2029 年 |
基准年 |
2021 |
历史岁月 |
2020(可定制至 2019 - 2014) |
定量单位 |
收入(百万美元),定价(美元) |
涵盖的领域 |
By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others) |
Countries Covered |
U.S., Canada and Mexico in North America. |
Market Players Covered |
AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others. |
Acute Coronary Syndrome Market Dynamics
Drivers
- Rise in prevalence of chronic diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.
- Growing Geriatric Population
The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in North America & Asia-Pacific region, creates an opportunity for market growth in the forecast period.
- Wide Range of Products Offered by Market Players
Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.
Opportunities
- Surge in Technological Advancements for Cardiovascular Disease
As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the North America acute coronary syndrome market in the forecast period.
Also, Governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Restraints/Challenges
Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.
The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.
This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid re-hospitalization, in a country where heart disease is on the rise.
North America Acute Coronary Syndrome Market Scope
North America acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Non-St-Elevation Myocardial Infarction
- St-Elevation Myocardial Infarction
- Unstable Angina
On the basis of type, the North America acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.
Diagnosis
- Stress Test
- Blood Tests
- Imaging
- Others
On the basis of diagnosis, the North America acute coronary syndrome market is segmented into stress test, blood test, imagining and others.
Treatment
- Medication
- Surgery
On the basis of treatment, the North America acute coronary syndrome market is segmented into medication and surgery.
End User
- Hospitals and Clinics
- Diagnostic Centers
- Academic Institutes
- Others
On the basis of end user, the North America acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.
Acute Coronary Syndrome Market Regional Analysis/Insights
North America acute coronary syndrome market is further segmented into major countries including the U.S., Canada, and Mexico.
The U.S. in North America dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in the country.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Acute Coronary Syndrome Market Share Analysis
North America Acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acute coronary syndrome market.
北美急性冠状动脉综合征市场的一些知名参与者包括 Movianto (美国)、Sharp (美国)、Thermo Fisher Scientific Inc.,(美国)、Catalent, Inc (美国)、PCI Pharma Services (美国)、Almac Group (英国)、PAREXEL International Corporation (美国)、Bionical Ltd. (英国)、Alium Medical Limited (英国)、MYODERM (英国)、Clinigen Group plc (英国)、Ancillare, LP (美国)、SIRO Clinpharm (印度) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (美国) Biocair (英国) 等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。如有进一步询问,请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ACUTE CORONARY SYNDROME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES, SUCH AS CORONARY ARTERY DISEASE, ISCHEMIC HEART DISEASE, AND VASCULAR DISEASES
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 WIDE RANGE OF PRODUCTS OFFERED BY MARKET PLAYERS
6.1.4 IMPROVING HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT POLICIES
6.2 RESTRAINTS
6.2.1 RISE IN COST OF THERAPEUTIC SURGERY
6.2.2 STRINGENT RULES & REGULATIONS
6.3 OPPORTUNITIES
6.3.1 SURGE IN TECHNOLOGICAL ADVANCEMENTS FOR CARDIOVASCULAR DISEASE
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 INCREASED REIMBURSEMENT POLICIES
6.3.4 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF ACCESSIBILITY OF SERVICES
6.4.2 LONG PROCESS OF APPROVAL BY REGULATORY BODIES
7 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE
7.1 OVERVIEW
7.2 NON-ST- ELEVATION MYOCARDIAL INFARCTION
7.3 ST-ELEVATION MYOCARDIAL INFARCTION
7.4 UNSTABLE ANGINA
8 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS
8.1 OVERVIEW
8.2 STRESS TEST
8.3 BLOOD TEST
8.4 IMAGING
8.5 OTHERS
9 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MEDICATION
9.3 SURGERY
10 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS AND CLINICS
10.3 DIAGNOSTIC CENTERS
10.4 ACADEMIC INSTITUTES
10.5 OTHERS
11 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVARTIS AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.1.5.1 PRODUCT EXPANSION
14.1.5.2 COLLABRATION
14.2 ASTRA ZENECA
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.2.5.1 ACQUISITION
14.3 AMGEN INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.4.5.1 ACQUISITION
14.5 BAXTER
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 ACQUISTION
14.7 PFIZER INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 MERCK & CO., INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.8.4.1 EVENT
14.8.4.2 ACQUISTION
14.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.9.3.1 PRODUCT APPROVAL
14.1 CSL
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 ACQUISITION
14.11 DAIICHI SANKYO COMPANY,LIMITED
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.11.4.1 PARTNERSHIP
14.12 JOHNSON & JOHNSON SERVICES, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.12.4.1 ACQUISITION
14.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.13.4.1 ACQUISITION
14.14 REGENERON PHARMACEUTICALS INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 LIST OF RECENT PROGRESS OF 3D BIO PRINTING FOR CARDIAC TISSUE ENGINEERING-
TABLE 2 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA NON-ST-ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA ST—ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA UNSTABLE ANGINA IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA STRESS TEST IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA BLOOD TEST IN ACUTE SYNDROME CORONARY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA IMAGING IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA MEDICATION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SURGERY IN ACUTE CORONARY SYNDROME MARKET, BY REGION 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA HOSPITALS AND CLINICS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA DIAGNOSTIC CENTERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA ACADEMIC INSTITUTES IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 21 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 22 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 23 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 U.S. ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 25 U.S. ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)
TABLE 26 U.S. ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 27 U.S. ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 CANADA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 CANADA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 30 CANADA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 31 CANADA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 MEXICO ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 33 MEXICO ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 34 MEXICO ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 35 MEXICO ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA ACUTE CORONNARY SYNDROME MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 11 RISING PREVALENCE OF CORONARY ARTERY DISEASE, ISCHEMIC HEART AND VASCULAR DISEASE AS WELL AS GROWING GERIATRIC POPULATION IS DRIVING THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET
FIGURE 14 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2021
FIGURE 15 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2021
FIGURE 19 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2021
FIGURE 23 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2021
FIGURE 27 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: SNAPSHOT (2021)
FIGURE 31 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021)
FIGURE 32 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE (2022-2029)
FIGURE 35 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.